Celgene wins NICE yes for Vidaza thanks to patient access scheme
This article was originally published in Scrip
Executive Summary
After six hearings and one appeal, Celgene has convinced NICE, the health technology appraisal institute for England and Wales, to recommend its life-extending anticancer (5-azacitidine) for treating NHS patients with myelodysplastic syndromes (MDS). A new patient access scheme persuaded the institute that the drug would be a cost-effective use of NHS resources.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.